Susan G. Komen®, the world’s main breast most cancers group, is awarding $21.7 million to fund 48 new analysis initiatives at 26 distinguished tutorial medical establishments within the US which might be targeted on enhancing affected person outcomes – significantly for individuals with probably the most aggressive breast cancers, or who’ve skilled a recurrence or metastasis. With this funding, Komen is now supporting greater than 152 lively analysis initiatives representing greater than $115 million in funding.
The funding we’re saying immediately in a broad portfolio of cutting-edge analysis will assist advance breast most cancers care and enhance outcomes for all individuals recognized with breast most cancers, together with underserved populations and people with few therapy choices. With this funding, we’re supporting a number of the high breast most cancers researchers who share our mission and giving everybody impacted by breast most cancers hope, as we transfer nearer to the cures for breast cancers.”
Victoria Wolodzko Good, SVP of Mission at Susan G. Komen
Of the whole $21.7 million awarded immediately:
- 79 % helps analysis targeted on probably the most aggressive breast cancers, metastasis and recurrence;
- 33 % helps scientific trials;
- 20 % helps analysis targeted on eliminating breast most cancers disparities;
“We nonetheless have a lot to study aggressive breast cancers and breast cancers that recur and metastasize. This essential analysis funding from Susan G. Komen will assist us unravel the biology of breast cancers to higher perceive the way to forestall breast most cancers recurrence and metastasis, and develop extra therapy choices, together with new therapies for individuals residing with metastatic breast most cancers,” stated Jennifer Pietenpol, Ph.D., Susan G. Komen Chief Scientific Advisor.
Pietenpol additionally serves because the Benjamin F. Byrd, Jr. Professor of Oncology, Chief Scientific and Technique Officer and Government Vice President for Analysis at Vanderbilt College Medical Middle.
Komen analysis grants are being awarded to the next research investigators at 26 preeminent US establishments:
Julie Palmer, Sc.D., MPH, Boston College
Jennifer Ligibel, MD, FASCO, Dana-Farber Most cancers Institute
Nancy Lin, MD, Dana Farber Most cancers Institute
Kornelia Polyak, MD, Ph.D., Dana-Farber Most cancers Institute
Sara Tolaney, MD, MPH, Dana Farber Most cancers Institute
Nikhil Wagle, MD, Dana Farber Most cancers Institute
Sunil Badve, MD, FRCPath, Emory College Faculty of Medication
Maria Sosa, Ph.D., Icahn Faculty of Medication at Mount Sinai
Tarah Ballinger, MD, Indiana College
Pedram Razavi, MD, Ph.D., Memorial Sloan Kettering Most cancers Middle
Jorge Reis-Filho, MD, Ph.D., FRCPath, Memorial Sloan Kettering Most cancers Middle
Sohrab Shah, Ph.D., Memorial Sloan Kettering Most cancers Middle
Lisa Coussens, Ph.D., Oregon Well being & Science College
Yibin Kang, Ph.D., Princeton College
Hai Wang, Ph.D., Roswell Park Most cancers Institute
Christina Curtis, Ph.D., MS, Stanford College Faculty of Medication
Melinda Telli, MD, Stanford College Faculty of Medication
Allison Kurian, MD, MSc, Stanford College Faculty of Medication
Haruka Itakura, MD, Ph.D., Stanford College Faculty of Medication
Daniel Hollern, Ph.D., The Salk Institute for Organic Research
Reshma Jagsi, MD, D.Phil., College of Michigan
Melissa Troester, Ph.D., College of North Carolina at Chapel Hill
Angela DeMichele, MD, MSCE, College of Pennsylvania
Adrian Lee, Ph.D., College of Pittsburgh
Steffi Oesterreich, Ph.D., College of Pittsburgh
Alana Welm, Ph.D., College of Utah Huntsman Most cancers Institute
Amelie Ramirez, PH, MPH, UT Well being San Antonio
Mariana Chavez MacGregor, MD, MSc, FASCO, UT MD Anderson Most cancers Middle
Sharon Giordano, MD, MPH, FASCO, UT MD Anderson Most cancers Middle
Srinivas Malladi, Ph.D., UT Southwestern Medical Middle
Tuya Pal, MD, Vanderbilt College Medical Middle
Ben Ho Park, MD, Ph.D., Vanderbilt College Medical Middle
Jennifer Pietenpol, Ph.D., Vanderbilt College Medical Middle
Sonya Reid, MD, Ph.D., Vanderbilt College Medical Middle
Cynthia Ma, MD, Ph.D., Washington College
Rulla Tamini, Sc.D., Weill Cornell School of Cornell College
Mariya Rozenblit, MD, Yale College
Lajos Pusztai, MD, D.Phil., Yale College
Komen has invested greater than $1 billion in breast most cancers analysis within the 40 years since its founding, greater than every other non-profit, and second solely to the US authorities.
